Innate Pharma reports consolidated annual revenues and other income stemming primarily from milestone payments, co-development cost-sharing agreements, and licensing collaborations with major pharmaceutical partners, hovering around 9 million Euros. Because the company operates as a clinical-stage research enterprise, its top-line revenue fluctuates significantly from year to year depending on the timing of execution milestones achieved within its drug discovery and licensing partnerships.